143 related articles for article (PubMed ID: 1438693)
1. Failla Memorial Lecture. Redox, radiation, and reductive bioactivation.
Adams GE
Radiat Res; 1992 Nov; 132(2):129-39. PubMed ID: 1438693
[TBL] [Abstract][Full Text] [Related]
2. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
3. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
Siim BG; Atwell GJ; Anderson RF; Wardman P; Pullen SM; Wilson WR; Denny WA
J Med Chem; 1997 Apr; 40(9):1381-90. PubMed ID: 9135035
[TBL] [Abstract][Full Text] [Related]
5. Nitro reduction as an electronic switch for bioreductive drug activation.
Siim BG; Denny WA; Wilson WR
Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242
[TBL] [Abstract][Full Text] [Related]
6. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
7. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB
Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
Papadopoulou MV; Ji M; Khan SH; Bloomer WD
Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.
Beall HD; Mulcahy RT; Siegel D; Traver RD; Gibson NW; Ross D
Cancer Res; 1994 Jun; 54(12):3196-201. PubMed ID: 8205540
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
[TBL] [Abstract][Full Text] [Related]
11. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
Wilson WR; Tercel M; Anderson RF; Denny WA
Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
[TBL] [Abstract][Full Text] [Related]
12. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.
Moselen JW; Hay MP; Denny WA; Wilson WR
Cancer Res; 1995 Feb; 55(3):574-80. PubMed ID: 7834627
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
Fourie J; Guziec F; Guziec L; Monterrosa C; Fiterman DJ; Begleiter A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):191-203. PubMed ID: 14614574
[TBL] [Abstract][Full Text] [Related]
14. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH; Wilson WR; Denny WA
Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-Specific Cytotoxins in Cancer Therapy.
Brown JM; Siim BG
Semin Radiat Oncol; 1996 Jan; 6(1):22-36. PubMed ID: 10717159
[TBL] [Abstract][Full Text] [Related]
16. [Hypoxic bioreductive agents: the possible immune and receptor-mediated mechanisms of antitumor action].
Shchepetkin IA
Eksp Klin Farmakol; 1999; 62(3):67-74. PubMed ID: 10439954
[TBL] [Abstract][Full Text] [Related]
17. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
18. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
[TBL] [Abstract][Full Text] [Related]
19. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.
Kennedy KA; Rockwell S; Sartorelli AC
Cancer Res; 1980 Jul; 40(7):2356-60. PubMed ID: 7388797
[TBL] [Abstract][Full Text] [Related]
20. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo.
Papadopoulou MV; Ji M; Bloomer WD
In Vivo; 1996; 10(1):49-57. PubMed ID: 8726811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
